Consultant: West Virginia city was bombarded with opioids
A new analysis of opioids in West Virginia shows the city of Huntington and its surrounding county were overwhelmed with shipments of prescription drugs (Source: ABC News: Health)
Source: ABC News: Health - May 10, 2021 Category: Consumer Health News Tags: Health Source Type: news
Younger Residents in Long-Term Care Find Meaning in Relationships, Engagement
Younger adults make up approximately 15% of the post-acute and long-term care patient population. They are more likely to be men and to have Medicaid as the primary payer (J Gerontol Nurs 2009;35:22-31). More younger adults in PALTC represent those with intellectual and developmental disabilities, individuals with neurological disorders such as multiple sclerosis and Huntington ’s disease, and those with serious mental illness. They are also more likely than their older counterparts to have experienced a traumatic injury that has resulted in profound loss of physical function due to hemiplegia or quadriplegia or loss of ...
Source: Caring for the Ages - April 28, 2021 Category: Health Management Authors: Elizabeth Galik Tags: Caring Collaborative Source Type: news
Protein linked to ALS/Ataxia could play key role in other neurodegenerative disorders
(University of Utah Health) A new study suggests that some neurological disorders share a common underlying thread. Staufen1, a protein that accumulates in the brains of patients with certain neurological conditions, is linked to amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease, along with other neurological disorders, including Alzheimer's, Parkinson's, and Huntington's disease, according to University of Utah Health scientists. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 15, 2021 Category: International Medicine & Public Health Source Type: news
Tensions increase among rival demonstrators in Huntington Beach
Clashes broke out among groups Sunday at the so-called White Lives Matter rally near the Huntington Beach Pier. (Source: Reuters: Health)
Source: Reuters: Health - April 11, 2021 Category: Consumer Health News Source Type: news
A new international consortium to promote stem cell-based therapy for Huntington's disease
(University of Barcelona) The Stem Cells for Huntington's Disease (SC4HD) is a new international consortium created to promote advanced therapy medicinal product (ATMP) through cell transplantation studies on Huntington's Disease. The entity, made up of twenty-eight renowned researchers from ten countries, has been officially presented in a recent publication in the Journal of Huntington's Disease. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 9, 2021 Category: International Medicine & Public Health Source Type: news
New Roche data at 2021 AAN highlight impact and breadth of expanding neuroscience portfolio
Basel, 8 April 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data for its approved and investigational medicines for the treatment of neurological disorders will be presented at the 73rd American Academy of Neurology (AAN) Annual Meeting being held virtually April 17-22, 2021. These new data include 23 abstracts highlighting the expanding Roche neuroscience portfolio across six therapeutic areas, including EVRYSDI ™ (risdiplam) for spinal muscular atrophy (SMA), OCREVUS® (ocrelizumab) in relapsing and primary progressive multiple sclerosis (RMS and PPMS), investigational Br...
Source: Roche Media News - April 8, 2021 Category: Pharmaceuticals Source Type: news
New Roche data at 2021 AAN highlight impact and breadth of expanding neuroscience portfolio
Basel, 8 April 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data for its approved and investigational medicines for the treatment of neurological disorders will be presented at the 73rd American Academy of Neurology (AAN) Annual Meeting being held virtually April 17-22, 2021. These new data include 23 abstracts highlighting the expanding Roche neuroscience portfolio across six therapeutic areas, including EVRYSDI ™ (risdiplam) for spinal muscular atrophy (SMA), OCREVUS® (ocrelizumab) in relapsing and primary progressive multiple sclerosis (RMS and PPMS), investigational Br...
Source: Roche Investor Update - April 8, 2021 Category: Pharmaceuticals Source Type: news
Roche provides update on tominersen programme in manifest Huntington ’s disease
Basel, 22 March 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the decision to discontinue dosing in the Phase III GENERATION HD1 study of tominersen in manifest Huntington ’s disease (HD). The decision was based on the results of a pre-planned review of the data from the Phase III study conducted by an unblinded Independent Data Monitoring Committee (iDMC). The iDMC made its recommendation based on the investigational therapy’s potential benefit/risk profile for s tudy participants. No new or emerging safety signals were identified for tominersen in the review of the data from this...
Source: Roche Investor Update - March 22, 2021 Category: Pharmaceuticals Source Type: news
Roche provides update on tominersen programme in manifest Huntington ’s disease
Basel, 22 March 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the decision to discontinue dosing in the Phase III GENERATION HD1 study of tominersen in manifest Huntington ’s disease (HD). The decision was based on the results of a pre-planned review of the data from the Phase III study conducted by an unblinded Independent Data Monitoring Committee (iDMC). The iDMC made its recommendation based on the investigational therapy’s potential benefit/risk profile for s tudy participants. No new or emerging safety signals were identified for tominersen in the review of the data from this...
Source: Roche Media News - March 22, 2021 Category: Pharmaceuticals Source Type: news
Huntington's disease driven by slowed protein-building machinery in cells
(Scripps Research Institute) The gene for Huntington's disease was found nearly 40 years ago, yet there are no approved treatments. A new study shows the problem may lie with slowed protein assembly. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 5, 2021 Category: International Medicine & Public Health Source Type: news
Big biotech, UCs launch $53M effort targeting Alzheimer's, other brain diseases
UCSF and UC Berkeley will receive $53 million over 10 years as part of a collaboration with biotech giant Genentech Inc. and its Swiss parent Roche to research potential new treatments for Alzheimer's, Huntington's and Parkinson's diseases, ALS, autism and other central nervous system conditions.
The partnership builds on a University of California-University of Washington effort started in 2019 and backed by the foundation of former Citibank CEO Sandy Weill and his wife, Joan, and it will initially… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - February 25, 2021 Category: Pharmaceuticals Authors: Ron Leuty Source Type: news
Big biotech, UCs launch $53M effort targeting Alzheimer's, other brain diseases
UCSF and UC Berkeley will receive $53 million over 10 years as part of a collaboration with biotech giant Genentech Inc. and its Swiss parent Roche to research potential new treatments for Alzheimer's, Huntington's and Parkinson's diseases, ALS, autism and other central nervous system conditions.
The partnership builds on a University of California-University of Washington effort started in 2019 and backed by the foundation of former Citibank CEO Sandy Weill and his wife, Joan, and it will initially… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - February 25, 2021 Category: Biotechnology Authors: Ron Leuty Source Type: news
New therapeutic target for Huntington's treatment
(University of Barcelona) Huntington's disease is caused by a mutation in the Huntingtin gene (HTT), which appears in adults and features motor, cognitive and psychiatric alterations. The origin of this disease has been associated with the anomalous functioning of the mutated protein: mHTT, but recent data showed the involvement of other molecular mechanisms. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 23, 2021 Category: International Medicine & Public Health Source Type: news
Basic cell health systems wear down in Huntington's disease, novel analysis shows
(Picower Institute at MIT) A new computational approach for analyzing complex datasets shows that as disease progresses, neurons and astrocytes lose the ability to maintain homeostasis. The " Geomic " approach can be applied to other diseases, authors say. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - February 23, 2021 Category: International Medicine & Public Health Source Type: news
After the Nobel, what next for Crispr gene-editing therapies?
Hailed as the ‘molecular scissors’ that will allow us to rewrite our genes, the DNA tool is being trialled in treatments for everything from sickle-cell anaemia to cancerWhen last year ’s Nobel prize for chemistry was awarded tobiochemist Jennifer Doudna and microbiologist Emmanuelle Charpentier for their work in developing the technique of gene editing known as Crispr-Cas9 (pronounced “crisper”), headlines hailed their discovery as “molecular scissors” that would allow us to “rewrite the book of life” – with all the complicated ethical questions that ability raises. But much of the excitement has nothi...
Source: Guardian Unlimited Science - February 21, 2021 Category: Science Authors: Philip Ball Tags: Gene editing Medical research Genetics Biology Science Cancer Huntington's disease Sickle cell disease Source Type: news
